Clinical Trial Update: ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies [Phase 1]

View source ↗

Summary

Acepodia Biotech's Phase 1 trial of ACE1831 in adults with relapsed/refractory CD20-expressing B-cell malignancies is currently recruiting across multiple B-cel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• High-grade B-cell Lymphoma
• Marginal Zone Lymphoma
• Mediastinal Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• ACE1831

Snippet

Sponsor: Acepodia Biotech, Inc. | Conditions: B-cell Lymphoma, Non Hodgkin Lymphoma | Phase 1 | Status: RECRUITING